Zivo Bioscience (Zivo Bioscience) Cash And Cash Equivalents : $0.14 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Zivo Bioscience Cash And Cash Equivalents?

Zivo Bioscience's quarterly cash and cash equivalents declined from Sep. 2023 ($1.49 Mil) to Dec. 2023 ($0.27 Mil) but then stayed the same from Dec. 2023 ($0.27 Mil) to Mar. 2024 ($0.14 Mil).

Zivo Bioscience's annual cash and cash equivalents declined from Dec. 2021 ($8.90 Mil) to Dec. 2022 ($1.80 Mil) and declined from Dec. 2022 ($1.80 Mil) to Dec. 2023 ($0.27 Mil).

Zivo Bioscience Cash And Cash Equivalents Historical Data

The historical data trend for Zivo Bioscience's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zivo Bioscience Cash And Cash Equivalents Chart

Zivo Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.35

0.14

8.90

1.80

0.27

Zivo Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.21	0.02	1.49	0.27	0.14

Zivo Bioscience Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Zivo Bioscience (OTCPK:ZIVO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Zivo Bioscience Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Zivo Bioscience's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Zivo Bioscience (Zivo Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zivo Bioscience Inc (OTCPK:ZIVO) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

21 East Long Lake Road, Suite 100, Bloomfield Hills, MI, USA, 48304

Website

https://www.zivobioscience.com

Zivo Bioscience Inc is a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's pipeline candidates are; Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Human Food Ingredients, and Skin Health.

Executives

Alison A Cornell	director	210 CARNEGIE CENTER, PRINCETON NJ 08540
Christopher D. Maggiore	officer: CHIEF FINANCIAL OFFICER	4788 NOBLES POND DR. NW, CANTON OH 44718
Nola E Masterson	director	768 WEST CALIFORNIA WAY, WOODSIDE CA 94062
John Bernard Payne	director	9900 NE 114TH CIRCLE, VANCOUVER WA 98662
Strome Mezzanine Fund, Lp	10 percent owner	100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Keith Marchiando	officer: Chief Financial Officer	C/O ZIVO BIOSCIENCE, INC., 21 E. LONG LAKE ROAD, SUITE 100, BLOOMFIELD HILLS MI 48304
Mark E Strome	10 percent owner	100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
Strome Alpha Fund L P	10 percent owner	100 WILSHIRE BLVD SUITE 1750, SANTA MONICA CA 90401
Strome Investment Management Lp	10 percent owner	100 WILSHIRE BLVD, 15TH FLOOR, SANTA MONICA CA 90401
Strome Group, Inc.	10 percent owner	100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Hep Investments Llc	10 percent owner	2804 ORCHARD LAKE RD, STE 205, KEEGO HARBOR MI 48320
Rondeau Robert O Jr	director	70 WEST LONG LAKE RD, STE 119, TROY MI 48098
Thomas Kevin Cox	director	470 MICHGAMME LANE, LAKE FOREST IL 60045
Andrew A Dahl	officer: President, CEO	7 WEST SQUARE LAKE ROAD, STE 6165, BLOOMFIELD HILLS MI 48302
Brian W Young	other: See remarks below.	1800 NW CORPORATE BLVD, BOCA RATON FL 33431